MonitorCRO   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Turkey (1999)

Organization Overview

First Clinical Trial
2014
NCT03020771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

MonitorCRO | Monitor CRO

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidiasis, Vulvovaginal (Phase 4)

Fatty Liver (Phase 2)

Fever (Phase 1)

Hemorrhagic Fever, Crimean (Phase 1)

Hemorrhagic Fevers, Viral (Phase 1)

Infections (Phase 4)

Liver Diseases (Phase 2)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pharyngitis (Phase 3)

Sclerosis (Phase 3)

Trichomonas Vaginitis (Phase 4)

Vaginal Diseases (Phase 4)

Vaginitis (Phase 4)

Vaginosis, Bacterial (Phase 4)

Vulvovaginitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 25